Cell therapy weekly: US FDA approves the first anti-BCMA CAR-T therapy for multiple myeloma

Written by RegMedNet

This week: the US FDA has approved Abecma (idecabtagene vicleucel; ide-cel) as the first BCMA-directed CAR-T cell immunotherapy for the treatment of adult patients with relapsed or refractory multiple myeloma, positive data has been reported for a Phase II trial investigating NurOwn® as a treatment for progressive multiple sclerosis, and an animal-free collagenase and neutral protease enzymes is now being offered by AMSBIO (in association with Nordmark Biochemicals). The news highlights: US FDA approves the first anti-BCMA CAR-T therapy for multiple myeloma Phase II study reports positive data for NurOwn® as a treatment for progressive multiple sclerosis Animal-free enzymes for...

To view this content, please register now for access

It's completely free